1. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision.;Daumer;J Neurol Sci,2009
2. 250microg or 500microg interferon beta-1b versus 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.;OConnor;Lancet Neurol,2009
3. Optimizing benefit of multiple sclerosis therapy: the importance of treatment adherence.;Patti;Patient Prefer Adherence,2009
4. Managed care considerations in treating multiple sclerosis.;Rich;Adv Study Pharm,2009
5. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.;Girouard;Patient Prefer Adherence,2011